Transcriptome analysis of low-risk and high-risk non-muscular invasive bladder cancer patients to reveal disease progression related genes.

483 Background: According to the EAU prognostic risk classes, non-muscle invasive bladder cancer (NMIBC) is divided into low, medium, and high risk. Patients with high-risk NMIBC (T1/Tis, with high grade/G3, or CIS) represent a challenging group as they are at greater risk of recurrence and progression.Our specific aim was to investigate the biomarkers associated with progression and recurrence in NMIBC. Methods: Tumor tissue were collected from 70 patients with bladder cancer, including high-risk NMIBC (n = 44),low-risk NMIBC (n = 10) and (n = 16) MIBC. mRNA sequenced using the ABclonal Whole RNA-seq Lib Prep kit.The differentially expressed genes were identified using DESeq2 and the analysis of the association between genes expression and patient survival with NMIBC cohorts data(Jakob et al., 2016). RNAseq data of human bladder cancer cell lines were achieved from the Cell Model Passports website (https://cellmodelpassports.sanger.ac.uk/). Results:A total of 456 genes are significantly high expressed in high-risk NMIBC group compared with the low-risk NMIBC group. Combined with MIBC expression data,we found 16 genes with consistently increasing expression from the low-risk NMIBC group to high-risk NMIBC group and MIBC group using a fold change of at least 2, and a false discovery rate (FDR) of 0.05.Among these genes,14 genes were also highly expressed in human bladder cancer cell lines. Survival analysis by Kaplan-Meier,we finally identified 13 high-expressed genes, including KRT6A、SPHK1、S100A9、SLC16A1、CDC25B、NELL2、PREX1、C15orf48、AKR1B10、CERCAM、PKMYT1、UCHL1、SLC16A1, were significantly associated with poor progression-free survival(p<0.05). Conclusions: We identified a set of 13 genes that may predict the progression of NMIBC and may serve as molecular targets for NMIBC therapy. these study results need to be confirmed in larger research studies.